# Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer

> **NCT00034541** · PHASE1,PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 32 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **BIOLOGICAL:** cetuximab
- **DRUG:** paclitaxel
- **DRUG:** carboplatin

## Key facts

- **NCT ID:** NCT00034541
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-12
- **Primary completion:** 2003-05
- **Final completion:** 2003-05
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2010-04-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00034541

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00034541, "Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00034541. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*